(CercleFinance.com) – AstraZeneca announces that a phase III trial involving the combination of capivasertib and Faslodex (fulvestrant) showed ‘a clinically and statistically significant improvement’ in progression-free survival (PFS) in patients with certain breast cancers, compared to the Faslodex + placebo protocol.
The results show that capivasertib + Faslodex resulted in a 40% reduction in the risk of disease progression or death compared to Faslodex + placebo in the overall trial population.
These promising data show that capivasertib could potentially change care practices and constitute a new treatment option.
This protocol may also delay disease progression, especially in patients who have become resistant to endocrine therapies and CDK4/6 inhibitors, says Nicholas Turner, MD, PhD, professor of molecular oncology at the Institute of Cancer Research of London.
The detailed results were presented today at the San Antonio Breast Cancer Symposium (SABCS).
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
